top of page

Alternative Products and Dermal Cosmetics Research Center (AMI)

IDENTIFICATION CODE: CZ.01.1.02 / 0.0 / 0.0 / 16_092 / 0008652


Expected completion of the project: 2017-2020


The project is focused on establishing a new research capacity of MB PHARMA through a balanced investment in instrumentation and new construction using a brownfield property. The Research Center for Alternative Products and Dermal Cosmetics (AMI) will focus on applied research and development in the areas of modern alternative products (homeopathy) and highly professional cosmetic products based on special enzymes (including intensive concentrates of own provenance). Alternative preparations for the treatment of inflammatory diseases are among the modern directions of treatment. Homeopathic treatment is today a fully recognized method in the field of alternative medicine. Sophisticated research and development focused on basic substances of the biological type, which is further modified in a precisely determined manner in accordance with the principles of GMP, for the production and preparation of mother tincture, which is then diluted and anchored (impregnated) in the final version of the medicinal product. MB PHARMA owns a GMP certificate issued by the state regulatory authority (SÚKL) for the production of DS of homeopathic types as one of the few companies in the world. Use in dermal cosmetics, especially in products that reduce hyperpigmentation or capillary damage (incl. Treatment of psoriasis), has been used since the end of the 20th century. The goal of development in the field of dermal cosmetics is the production of own enzymes and / or modernization of used analytical processes (eg RT-PCR, DNA isolator, UPLC-UV-MS) with an emphasis on the development and research of new medicinal products under GMP. The goal of development in the field of homeopathics is mainly the use of an induced bacterial expression system. Our collection of microorganisms, which is also certified by the state authority (SÚKL) within the GMP, includes a large number of isolated and acquired bacterial (and viral) strains. The main focus of the project is based on G + bacteria. However, the G project will also target G-bacteria such as Escherichia coli. This is because these systems can increase the production of the required enzymes, and a more efficient purification method can avoid losses throughout the biotechnological production process.



European Regional Development Fund

OP Enterprise and Innovation for Competitiveness

bottom of page